Review
Oncology
Shiekhah M. Alzahrani, Huda A. Al Doghaither, Ayat B. Al-Ghafari, Peter N. Pushparaj
Summary: Although 5-FU-based chemotherapy is widely used for colorectal cancer, it has limitations. Capecitabine, a prodrug of 5-FU, was developed to overcome these drawbacks and achieve more convenient therapy. This review compares the properties and efficacy of 5-FU therapy and capecitabine therapy, including drug metabolism, cellular mechanisms, safety, and tolerability. Future research should explore the combination of capecitabine with novel drugs to inhibit tumor initiation, progression, and metastasis.
Article
Oncology
Yanyun Gao, Philipp Zens, Min Su, Camila Anna Gemperli, Haitang Yang, Haibin Deng, Zhang Yang, Duo Xu, Sean R. R. Hall, Sabina Berezowska, Patrick Dorn, Ren-Wang Peng, Ralph Alexander Schmid, Wenxiang Wang, Thomas Michael Marti
Summary: The study revealed that the cytidine analogue 5'-DFCR selectively targets chemotherapy-resistant A549 paraclone cells characterized by high CDA and TYMP expression. Chemotherapy increases CDA and TYMP expression, rendering resistant lung cancer cells susceptible to subsequent 5'-DFCR treatment.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2021)
Article
Medicine, Research & Experimental
Nathalia D. de Moura Sperotto, Rodrigo Braccini Madeira Silva, Marcia Alberton Perello, Ana Flavia Borsoi, Adilio da Silva Dadda, Candida Deves Roth, Raquel Dal Sasso Freitas, Ana Paula Duarte de Souza, Deise do Nascimento de Freitas, Jaqueline Nascimento Picada, Jayne Torres de Sousa, Debora Dreher Nabinger, Stefani Altenhofen, Carla Denise Bonan, Valnes S. Rodrigues-Junior, Cristiano Valim Bizarro, Luiz Augusto Basso, Pablo Machado
Summary: The study investigated the effects of the hTP inhibitor CPBMF-223 in a xenograft tumor model induced by human colorectal carcinoma cells, showing significant inhibition of tumor growth, reduction in vessel number, and decrease in cell migration. Additionally, CPBMF-223 demonstrated a favorable toxicity profile and pharmacokinetic characteristics, highlighting its potential as a promising drug candidate for colorectal cancer.
BIOMEDICINE & PHARMACOTHERAPY
(2021)
Article
Oncology
Eiji Oki, Akitaka Makiyama, Yuji Miyamoto, Masahiko Kotaka, Hirofumi Kawanaka, Keisuke Miwa, Akira Kabashima, Tomohiro Noguchi, Kotaro Yuge, Tomomi Kashiwada, Koji Ando, Mototsugu Shimokawa, Hiroshi Saeki, Yoshito Akagi, Hideo Baba, Yoshihiko Maehara, Masaki Mori
Summary: The study assessed the efficacy and safety of FTD/TPI plus Bev in elderly patients with previously untreated metastatic colorectal cancer, showing it to be an effective and well-tolerated regimen. The primary endpoint of PFS was 9.4 months, with a median OS of 22.4 months, an ORR of 40.5%, and a disease control rate of 86.5%.
Review
Genetics & Heredity
Tony M. Mertz, Christopher D. Collins, Madeline Dennis, Margo Coxon, Steven A. Roberts
Summary: The occurrence and development of cancer are closely related to mutations, and dysregulated activity of APOBECs can lead to mutations. The study of mutation signatures helps us understand the patterns and processes of mutations. In humans, APOBEC-generated genetic heterogeneity plays an important role in cancer development, metastasis, and resistance to therapy.
ANNUAL REVIEW OF GENETICS
(2022)
Article
Oncology
I. Bijnsdorp, Godefridus J. Peters
Summary: The study found that resistance to rapamycin in TP-expressing cancer cells may be related to thymidine-mediated autophagy activation, and thymidine-induced mTOR signaling is correlated with TP expression levels.
CANCER DRUG RESISTANCE
(2021)
Article
Oncology
Donia Kaidi, Louis Szeponik, Ulf Yrlid, Yvonne Wettergren, Elinor Bexe Lindskog
Summary: This study found that high TYMP expression in tumor epithelial cells is associated with shorter relapse-free survival in stage II CRC patients. Tissue microdissection is important for accurate analysis. Further research is needed to explore the clinical relevance of TYMP and CD163 in identifying high-risk stage II patients who may benefit from adjuvant chemotherapy.
CLINICAL & TRANSLATIONAL ONCOLOGY
(2022)
Article
Oncology
Sundaramoorthy Revathidevi, Avaniyapuram Kannan Murugan, Hirofumi Nakaoka, Ituro Inoue, Arasambattu Kannan Munirajan
Summary: Cervical cancer, a common cancer in women, is primarily caused by HPV infection. Apart from genetic and epigenetic factors, the APOBEC3 family plays a crucial role in the molecular pathogenesis of cancer, including inducing tumor mutations through DNA editing mechanisms.
Article
Immunology
Sai Zhang, Zhenglu Wang, Shunli Fan, Tao Liu, Sei Yoshida, Shuang Yang, Lei Liu, Wen Hou, Lei Cao, Jianxi Wang, Zhuolun Song, Shanni Li, Sirui Zhang, Hao Wang, Jianghong Li, Hong Zheng, Zhongyang Shen
Summary: Capacitabine is widely used in the treatment of digestive system tumors, and studies have shown its immunosuppressive effects through reduction of T cell proportions, pro-inflammatory cytokines, and induction of T cell apoptosis via TP expression, ERS induction, ROS production, and mitochondria-mediated apoptosis activation.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Guo-Zheng Pang, Ya-Hui Zhao, Yuan-Xian Wang, Shao-Qin Rong, Hai Gao, Dan Zhou
Summary: Oxidized methylcytidines 5-hydroxymethyl-20deoxycytidine (5hmdC) and 5-formy-20deoxycytidine (5fdC) are deaminated by cytidine deaminase (CDA) into genome-toxic variants of uridine, triggering DNA damage and cell death. Our study found that cancer cells infected with mycoplasma exhibited increased sensitivity to 5hmdC and 5fdC, independent of CDA expression. Biochemical assays showed that mycoplasma CDA was capable of deaminating 5hmdC and 5fdC, and administration of Tetrahydrouridine (THU) attenuated the effect, suggesting that intratumoral microbes could enhance the tumor-killing effect of oxidized methylcytidines.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
(2023)
Article
Oncology
Kyung U. Hong, Afi H. Tagnedji, Mark A. Doll, Kennedy M. Walls, David W. Hein
Summary: This study observed the upregulation of cytidine deaminase (CDA) in multiple breast cancer cell lines due to NAT1 deletion. It was found that NAT1 KO cells showed increased sensitivity to 5fdC, which depended on their increased CDA activity. These findings provide a new therapeutic strategy for treating breast cancer with elevated NAT1 expression.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Oncology
Muneyuki Koyama, Erika Osada, Nubutake Akiyama, Ken Eto, Yoshinobu Manome
Summary: This study indicates that demethylating agent alone does not enhance the cytotoxicity of 5-FU against colorectal cancer cells. To increase sensitivity to 5-FU, combination with adjuvant therapy focusing on metabolic pathways other than the TYMP pathway seems necessary.
ANTICANCER RESEARCH
(2022)
Article
Biochemistry & Molecular Biology
Haejeong Heo, Jong-Hwan Kim, Hyun Jung Lim, Jeong-Hwan Kim, Miso Kim, Jaemoon Koh, Joo-Young Im, Bo-Kyung Kim, Misun Won, Ji-Hwan Park, Yang-Ji Shin, Mi Ran Yun, Byoung Chul Cho, Yong Sung Kim, Seon-Young Kim, Mirang Kim
Summary: Targeting cytidine deaminase metabolism represents a potential new therapeutic strategy for overcoming ALK inhibitor resistance in non-small-cell lung cancer.
EXPERIMENTAL AND MOLECULAR MEDICINE
(2022)
Article
Immunology
Ankush Paladhi, Samrat Daripa, Indrani Mondal, Sumit Kumar Hira
Summary: T-cell exhaustion plays a crucial role in the resistance of microsatellite-stable colorectal cancer to immunotherapy. Targeting thymidine phosphorylase (TYMP) can induce immunological cell death and enhance the effects of immunotherapy. Additionally, chemoimmunotherapy can convert Treg cells into Th1 effector cells, leading to increased infiltration and activation of cytotoxic T lymphocytes.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Salvatore Benfatto, Ozdemirhan Sercin, Francesca R. Dejure, Amir Abdollahi, Frank T. Zenke, Balca R. Mardin
Summary: PARIS is a machine learning approach that predicts synthetic lethal interactions by combining CRISPR viability screens with genomics and transcriptomics data. The method identified 15 high confidence synthetic lethal interactions within DNA damage repair genes, with potential therapeutic targets such as BRIP1 in tumors expressing low levels of ALDH2. The platform shows promise in improving cancer therapy with the increasing availability of cancer genomics data.
Review
Medicine, General & Internal
Qingyang Xiao, Andre Nobre, Pilar Pineiro, Miguel-Angel Berciano-Guerrero, Emilio Alba, Manuel Cobo, Volker M. Lauschke, Isabel Barragan
JOURNAL OF CLINICAL MEDICINE
(2020)
Article
Medicine, General & Internal
Javier Espildora-Hernandez, Tania Diaz-Antonio, Javier Baena-Espinar, Inmaculada Alonso-Calderon, Jose Rioja, Emilio Alba-Conejo, Pedro Valdivielso, Miguel-Angel Sanchez-Chaparro
JOURNAL OF CLINICAL MEDICINE
(2020)
Article
Pharmacology & Pharmacy
Sara Ruiz-Pinto, Guillermo Pita, Miguel Martin, Rocio Nunez-Torres, Ana Cuadrado, Marta N. Shahbazi, Daniela Caronia, Alexander Kojic, Leticia T. Moreno, Julio C. de la Torre-Montero, Maria Lozano, Luis A. Lopez-Fernandez, Nuria Ribelles, Jose A. Garcia-Saenz, Emilio Alba, Roger L. Milne, Ana Losada, Mirna Perez-Moreno, Javier Benitez, Anna Gonzalez-Neira
Summary: The study identified novel genetic factors associated with Capecitabine-induced hand-foot syndrome (CiHFS) and revealed a molecular mechanism underlying individual genetic susceptibility, with implications for clinically relevant risk prediction.
CLINICAL PHARMACOLOGY & THERAPEUTICS
(2021)
Review
Ophthalmology
Carmen Alba-Linero, Emilio Alba
Summary: Ocular toxicities in patients treated with checkpoint inhibitors are not clearly defined and are often underestimated in clinical trials. Early ophthalmic examination and treatment with corticosteroids may improve the visual prognosis for these patients.
SURVEY OF OPHTHALMOLOGY
(2021)
Article
Oncology
Nuria Ribelles, Jose M. Jerez, Pablo Rodriguez-Brazzarola, Begona Jimenez, Tamara Diaz-Redondo, Hector Mesa, Antonia Marquez, Alfonso Sanchez-Munoz, Bella Pajares, Francisco Carabantes, Maria J. Bermejo, Ester Villar, Maria E. Dominguez-Recio, Enrique Saez, Laura Galvez, Ana Godoy, Leo Franco, Sofia Ruiz-Medina, Irene Lopez, Emilio Alba
Summary: This study developed predictive models for response in HR+/HER2-negative metastatic breast cancer patients using machine learning methods, finding that models based on NLP free-text processing are slightly better than those based on manually extracted data.
EUROPEAN JOURNAL OF CANCER
(2021)
Article
Oncology
N. Ribelles, I. Alvarez-Lopez, A. Arcusa, J. I. Chacon, J. de la Haba, J. Garcia-Corbacho, J. Garcia-Mata, C. Jara, J. M. Jerez, M. Lazaro-Quintela, L. Leon-Mateos, N. Ramirez-Merino, A. Tibau, A. Garcia-Palomo
Summary: The study found that electronic health records (EHRs) are widely implemented in oncology departments in hospitals in Spain and are generally viewed positively for improving work organization and clinical practice. However, there are limitations such as insufficient information inclusion and increased workload that hinder their use for research purposes.
CLINICAL & TRANSLATIONAL ONCOLOGY
(2021)
Article
Oncology
Jose Manuel Perez-Garcia, Geraldine Gebhart, Manuel Ruiz Borrego, Agostina Stradella, Begona Bermejo, Peter Schmid, Frederik Marme, Santiago Escriva-de-Romani, Lourdes Calvo, Nuria Ribelles, Noelia Martinez, Cinta Albacar, Aleix Prat, Florence Dalenc, Khaldoun Kerrou, Marco Colleoni, Noemia Afonso, Serena Di Cosimo, Miguel Sampayo-Cordero, Andrea Malfettone, Javier Cortes, Antonio Llombart-Cussac
Summary: The study evaluates early metabolic responses to neoadjuvant trashizumab and pertuzumab using F-18-FDG-PET and the possibility of chemotherapy de-escalation using a pathological response-adapted strategy in patients with HER2-positive, early-stage breast cancer.
Article
Oncology
Cristina Roldan-Jimenez, Bella Pajares, Sofia Ruiz-Medina, Manuel Trinidad-Fernandez, Manuel Gonzalez-Sanchez, Nuria Ribelles, Jose Manuel Garcia-Almeida, Maria Jose Rios-Lopez, Emilio Alba, Antonio Ignacio Cuesta-Vargas
Summary: The study introduces a community-based Onco-Health Club (OHC) for breast cancer survivors (BCS), combining therapeutic exercise intervention and nutritional education to improve quality of life, physical function, and reduce cancer-related fatigue over a 3-month period. Data on recruitment, compliance, and potential limitations were collected, indicating a need for further research to optimize patient engagement and compliance in clinical settings.
SUPPORTIVE CARE IN CANCER
(2022)
Article
Oncology
Sofia Ruiz-Medina, Silvia Gil, Begona Jimenez, Pablo Rodriguez-Brazzarola, Tamara Diaz-Redondo, Mireya Cazorla, Marta Munoz-Ayllon, Inmaculada Ramos, Carmen Reyna, Maria Jose Bermejo, Ana Godoy, Esperanza Torres, Manuel Cobo, Laura Galvez, Antonio Rueda, Emilio Alba, Nuria Ribelles
Summary: The COVID-19 pandemic has significantly decreased the number of cancer diagnoses, especially in breast cancer, colorectal neoplasms, and head and neck tumors. Health systems must take necessary measures to restore pre-pandemic diagnostic procedures and recover lost patients who have not been diagnosed.
Article
Rehabilitation
Cristina Roldan-Jimenez, Jaime Martin-Martin, Bella Pajares, Nuria Ribelles, Emilio Alba, Antonio Cuesta-Vargas
Summary: Breast cancer survivors may experience impaired upper limb function after surgery, which can be influenced by various factors. This study found that greater upper limb function was associated with higher grip strength, lower fear-avoidance behavior, and fewer central sensitization symptoms among breast cancer survivors. These variables accounted for 45% of the variance in upper limb function, highlighting the importance of considering strength, fear avoidance, and central sensitization symptoms when designing interventions to improve upper limb function in breast cancer survivors.
Article
Rehabilitation
Antonio Cuesta-Vargas, Jena Buchan, Emilio Alba, Marcos Iglesias Campos, Cristina Roldan-Jimenez, Bella Pajares
Summary: A physical function test based on lie-to-sit transition was developed and its feasibility in patients with metastatic breast cancer (MBC) was studied. The 30-second lie-to-sit test showed to be a feasible functional and submaximal test in a sample of MBC.
DISABILITY AND REHABILITATION
(2023)
Article
Anesthesiology
David Perez-Cruzado, Cristina Roldan-Jimenez, Marcos Iglesias-Campos, Bella Pajares, Emilio Alba, Antonio Cuesta-Vargas
Summary: This study assessed the psychometric properties of the Spanish version of the Pain Catastrophizing Scale (PCS) in Spanish breast cancer survivors. The results showed that the PCS is a valid and reliable instrument for evaluating pain catastrophizing, and it can help clinicians manage pain and measure the effectiveness of interventions.
Correction
Oncology
Jose Angel Garcia-Saenz, Isabel Blancas, Isabel Echavarria, Carmen Hinojo, Mireia Margeli, Fernando Moreno, Sonia Pernas, Teresa Cajal, Nuria Ribelles, Meritxell Bellet
CLINICAL & TRANSLATIONAL ONCOLOGY
(2023)
Article
Oncology
Jose Angel Garcia-Saenz, Isabel Blancas, Isabel Echavarria, Carmen Hinojo, Mireia Margeli, Fernando Moreno, Sonia Pernas, Teresa Ramon y Cajal, Nuria Ribelles, Meritxell Bellet
Summary: Advanced breast cancer poses challenges for patients and physicians due to the genomic changes that lead to treatment resistance. The primary goal is to enhance patients' quality of life and survival through appropriate subsequent therapies based on understanding the disease's natural progression. These guidelines provide a summary of the current evidence and available medical management options for advanced breast cancer.
CLINICAL & TRANSLATIONAL ONCOLOGY
(2023)